Cessatech A/S

ACTIVE

Denmarkwww.cessatech.comPublic1–10 employeesEstablished: 2020-01-01

Clinical Trials

3 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2020

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

62.5%

Phase 2

37.5%

Trial Status Distribution

Active, not recruiting

37.5%

Completed

50.0%

Recruiting

12.5%

Clinical Trials

Trials sponsored by this organization (8)

Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients

Phase 2

Completed

interventional

May 2024155 participants

Open-label, prospective study to assess the safety, tolerability, analgesic effect and feasibility of IN SUF/KET in pediatric patients with moderate or severe pain, in an acute care setting

Phase 1

Recruiting

interventional

Jul 2023150 participants

Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001

Phase 2

Completed

interventional

Sep 2022220 participants

Analgesic Efficacy and Pharmacokinetic-pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001 after Impacted Mandibular Third Molar Extractio

Phase 1

Active, not recruiting

Nov 2021300 participants

Pharmacokinetic Study of Intranasal CT001 in Children 1-17 Years of Age Undergoing Elective Surgical Procedures

Phase 2

Completed

interventional

Aug 202125 participants

Study of CT001 in Healthy Volunteers

Phase 1

Completed

interventional

Mar 202114 participants

asal spray (CT001) as pain medication before anesthesia in planned surgical procedures - A study of pharmacokinetics in children and adolescents aged 1-17 years

Phase 1

Active, not recruiting

Mar 202130 participants

Clinical trial investigating bioavailability of sufentanil and ketamine in combination as nasal spray in healthy male volunteers

Phase 1

Active, not recruiting

Dec 202012 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations